文献速递肿瘤 PET/CT

68Ga-PSMA PET/CT在主动监测中的应用:从影像到知情决策的「哨箭」视角

[68Ga]Ga-PSMA PET/CT in active surveillance: From imaging to informed decision-making - a "Whistling Arrow" perspective.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-02-24

本文综述了68Ga-PSMA PET/CT在前列腺癌主动监测(AS)中的应用前景。低风险前列腺癌患者穿刺活检的ISUP 1级常低估真实分级,PSMA PET/CT有望补充mpMRI与靶向活检的不足。PRIMARY2、CONFIRM、BiPASS等前瞻性研究正在评估其价值,伊斯坦布尔PSMA PET/CT标准(IPPC)与I-SELECT研究为AS风险分层提供结构化框架。

要点

  • 穿刺ISUP 1级常低估肿瘤分级,AS路径存在诊断不确定性
  • PSMA表达与肿瘤侵袭性相关,支持其用于csPCa检出
  • IPPC为AS候选者提供结构化、可重复的摄取值分类方法

核心结论

  • 68Ga-PSMA PET/CT有望作为主动监测中识别临床显著前列腺癌的补充工具,但需前瞻性研究验证。

研究设计与样本

  • 本文为综述,汇总PSMA PET/CT在主动监测领域的研究现状与正在开展的前瞻性研究。

主要发现

  • 穿刺活检ISUP 1级常低估真实肿瘤分级,造成AS路径中的诊断不确定性。
  • PSMA表达与肿瘤侵袭性相关的证据支持PSMA PET/CT作为补充工具。
  • 现有基于PET的评估方法并非专为AS设计,其在穿刺后低风险人群中的性能尚待确立。

关键数值与推荐

  • IPPC整合形态学特征、摄取强度与延迟盆腔显像,用于穿刺后ISUP 1–2级拟行AS者的风险分层。

临床怎么用

  • 对拟行主动监测的ISUP 1–2级患者,可参考IPPC框架对前列腺内PSMA摄取进行结构化分类以辅助风险分层。

局限性

  • 现有PET评估方法非专为AS设计,在穿刺后低风险人群中的性能尚未确立。
  • 相关前瞻性研究(PRIMARY2、CONFIRM、BiPASS、I-SELECT)仍在进行中,结论待定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Active surveillance (AS) is a central management strategy for men with low-risk prostate cancer, aiming to avoid overtreatment while preserving the opportunity for curative intervention if progression occurs. A key challenge, however, is the accurate identification of clinically significant prostate cancer (csPCa) at baseline. Despite the integration of multiparametric MRI (mpMRI) and targeted biopsy into routine practice, biopsy-derived ISUP Grade Group 1 frequently underestimates true tumor grade, contributing to diagnostic uncertainty within AS pathways. Prostate-specific membrane antigen (PSMA) PET/CT has emerged as a potential complementary tool, supported by evidence linking PSMA expression with tumor aggressiveness. Ongoing prospective studies—PRIMARY2, CONFIRM and BiPASS—are evaluating whether PSMA PET can refine detection of csPCa, reduce false-negative biopsies and inform patient selection. However, existing PET-based assessment approaches were not specifically designed for AS, and their performance in post-biopsy, low-risk populations remain to be established. The Istanbul PSMA PET/CT Criteria (IPPC) were developed to provide a structured, reproducible method for categorizing intraprostatic PSMA uptake in men with ISUP Grade Group 1–2 disease being considered for AS. IPPC integrates morphological features, uptake intensity and delayed pelvic imaging to support risk stratification after biopsy. The ongoing I-SELECT study is designed to explore whether this framework can improve csPCa detection and guide AS decision-making in clinical practice.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Kabasakal L. [68Ga]Ga-PSMA PET/CT in active surveillance: From imaging to informed decision-making - a "Whistling Arrow" perspective. Eur J Nucl Med Mol Imaging. 2026. PMID: 41733628. doi:10.1007/s00259-026-07806-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。